m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04137)
Name
Ifabotuzumab
Status
Phase 2
TTD Drug ID
D08NZG
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Ephrin type-A receptor 3 (EPHA3)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-A receptor 3 (EPHA3) is a therapeutic target for Ifabotuzumab. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ifabotuzumab through regulating the expression of Ephrin type-A receptor 3 (EPHA3). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-A receptor 3 (EPHA3) is a therapeutic target for Ifabotuzumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ifabotuzumab through regulating the expression of Ephrin type-A receptor 3 (EPHA3). [1], [2]
References
Ref 1 m(6)A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells. Cell Rep. 2017 Mar 14;18(11):2622-2634. doi: 10.1016/j.celrep.2017.02.059.
Ref 2 Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. doi: 10.1021/jm9009444.